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Polyductin, the PKHD1 gene product, comprises isoforms ex-
pressed in plasma membrane, primary cilium, and cytoplasm.
Background. PKHD1, the autosomal-recessive polycystic
kidney disease (ARPKD) gene, encodes multiple alternatively
spliced transcripts predicted to generate membrane-bound and
secreted proteins. The longest open reading frame encodes poly-
ductin (fibrocystin), a putative 4074 amino acid protein with a
single transmembrane domain and an intracellular C-terminus.
Methods. To characterize the PKHD1 products and their ex-
pression profile, we raised polyclonal antibodies against differ-
ent portions of polyductin and analyzed different organs using
various methods.
Results. Western blot analyses demonstrated specific bands
of >440 kD in human adult kidney, liver, and pancreas and
∼230 kD in kidney and liver, predominantly observed in mem-
brane fractions. The >440-kD putative membrane protein was
immunoprecipitated from kidney and subsequently detected
by Western blotting using two distinct antisera. An additional
product of ∼140 kD was specifically recognized by affinity-
purified antisera predominantly in soluble fractions. Immuno-
histochemistry studies revealed specific staining in cortical and
medullary collecting ducts and thick ascending limbs of Henle
(TALH). Serial sections were stained with antibodies against
aquaporin-2 and Tamm-Horsfall protein to confirm the nephron
segment localization. Positive staining was also detected in bil-
iary and pancreatic duct epithelia. Analyses of mouse develop-
ing tissues showed specific staining in the ureteric bud branches,
intra- and extrahepatic biliary ducts, pancreatic ducts, and sali-
vary glands. Immunofluorescence studies in inner medullary
collecting duct cultured cells and immunoelectron microscopy
analysis of medullary collecting ducts demonstrated that the
protein localizes to the primary cilium. Positive signal was also
detected in the apical membrane and in cytoplasm.
Conclusion. The results indicate that polyductin is part of the
group of polycystic kidney disease (PKD)-related proteins ex-
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pressed in primary apical cilia. Our data also suggest that, in ad-
dition to its likely involvement in cilia function, polyductin prob-
ably serves in other subcellular functional roles. The detection
of three different products using two antisera, with evidence for
distinct subcellular localizations, suggests that PKHD1 encodes
membrane-bound and soluble isoforms.
Several mechanisms may be involved in renal cysto-
genesis and cyst enlargement [1]. The polycystic kidney
diseases (PKD) constitute a particularly important group
among the renal cystic disorders, given their significant
morbidity and mortality in humans. The identification of
several PKD-associated genes and the characterization
of their corresponding products have recently revealed
that primary cilia may play a pivotal role in renal epithe-
lial function and that disruption of ciliary structure or
function may participate in the pathogenesis of PKD [2,
3].
Autosomal-recessive polycystic kidney disease
(ARPKD) is a major cause of pediatric PKD, with an
estimated incidence of 1:20,000 live births [4]. The dis-
ease is characterized by fusiform or cylindric dilatation
of renal collecting ducts and biliary dysgenesis [5]. While
most of the cases are diagnosed early in infancy, the
ARPKD clinical spectrum is broad, including the severe
perinatal phenotype as well as milder and later onset
presentations [6].
All typical forms of ARPKD are caused by muta-
tions in a single gene, PKHD1 (polycystic kidney and
hepatic disease 1) [7, 8]. This gene was recently iden-
tified by positional cloning and by the characterization
of an orthologous gene in the pck rat model [9, 10].
PKHD1 is a very large gene, extending over an at least
469 kb genomic segment and including a minimum of
86 exons. Its exons are assembled in a complex pat-
tern of alternative splice variants, giving rise to a large
number of transcripts that are potentially translated into
1345
1346 Menezes et al: Polyductin expression profile
membrane-bound and secreted protein products [9]. A 67
exon transcript encodes the putative longest open read-
ing frame (ORF), predicted to yield a single transmem-
brane glycoprotein of 4074 amino acids, polyductin. In its
unglycosylated form, polyductin is expected to have a
molecular weight of ∼447 kD. Its extracellular portion
contains more than 3800 amino acids and includes a se-
ries of immunoglobulin-like-plexin-transcription factor
(IPT) domains in the amino terminus and multiple par-
allel beta-helix 1 (PbH1) repeats between the last IPT
and the transmembrane domain. The protein short car-
boxyl tail includes putative cyclic adenosine monophos-
phate (cAMP)/cyclic guanosine monophosphate (cGMP)
phosphorylation sites that may be important for its
function.
PKHD1 is expressed at its highest level in adult and
fetal kidney, suggesting that, in addition to its role in
kidney development, the gene is also functionally impor-
tant in the mature organ [9]. Expression at significantly
lower levels was also detected in pancreas and liver. Initial
structural analyses revealed significant homology with
a superfamily of proteins involved in regulation of cell
proliferation and cell adhesion/repulsion, including hep-
atocyte growth factor receptor (HGFR) and plexins [11,
12]. In a recent work, we isolated the mouse ortholog,
Pkhd1, and showed that the basic properties of the human
gene are conserved in mouse, including the complicated
splicing pattern [13]. In addition, expression analyses of
Pkhd1 in different organs support the existence of specific
exon arrangement transcripts in different structures and
tissues.
A set of five studies performed to date revealed the
first genotype-phenotype correlations in ARPKD pa-
tients [9, 10, 14–16]. The most significant observation
was that all patients with two mutations truncating the
longest ORF product had the severe phenotype. The po-
tentially pathogenic mutations were found to be scat-
tered throughout the gene. More recently, Ward et al [17]
have shown that polyductin is expressed in the branching
ureteric bud and in collecting ducts and that the protein
is expressed in primary cilia of Madin-Darby canine kid-
ney (MDCK) cells. Expression has also been described
in cholangiocyte cilia [18].
In our current work, we sought to study the poly-
ductin expression profile in human adult and in mouse
developing tissues using a comprehensive approach.
This study supports our previous hypothesis, showing
that PKHD1 encodes products that apparently include
membrane-anchored and soluble isoforms. We have de-
tected a product that likely represents the longest ORF-
related protein and shown that polyductin is expressed in
the primary apical cilium and in the apical membrane.
These observations should provide an important plat-
form for determining polyductin function and the disease
pathogenesis.
METHODS
Polyclonal antibodies generation
To characterize the PKHD1 translation products and
their expression profile, we raised polyclonal antibodies
against different portions of the longest ORF prod-
uct using fusion protein and synthetic peptide-based
strategies. Two fusion proteins and six short synthetic
peptides were included in the immunization protocol.
Polyclonal antisera against one of the fusion proteins
[fusion protein 2 (FP2)] and two short peptides [peptides
5 and 6 (P5P6)] were validated, showing sensibility
and specificity to detect polyductin. These two an-
tisera and respective preimmune sera were used to
perform all the experiments shown in this work. The
gene fragment used for FP2 production encoded the
polyductin intracellular C-terminus (amino acids 3884
to 4074), coupled to a polyhistidine N-terminus. The
corresponding cDNA fragment was amplified from the
cDNA clone 4.1, described in our previous report [9].
The amplicon was generated using the BamH1 or EcoRI
restriction site-containing primers FP2 forward 5′-
GCGCGGATCCAGAAGCAAAAGCAGAAAAAC-
3′, and FP2 reverse 5′-GCGCGAATTCTCACAGTTG
CTCCTCAATAG-3′. The digested insert was cloned
into pAE (kindly provided by P. Ho, Instituto Butantan,
Sa˜o Paulo, Brazil), a pET-3-His–derived vector. The
6-His-polyductin fusion proteins were produced in
BL21(DE3) pLysS Escherichia coli, purified in Poly-Prep
columns (EUA) (Bio-Rad, Hercules, CA, USA) with
Ni-NTA agarose resin (Qiagen, Germany) and eluted
with urea buffer (8.0 mol/L urea, 0.1 mol/L NaH2PO4,
0.01 mol/L Tris HCl, pH 4.5). The a-P5P6 antiserum was
raised against the amino acid sequences 3252 to 3266
(P5) and 3774 to 3785 (P6).
The immunization process was carried out in rabbits
for both fusion proteins and synthetic peptides, and the
antisera were subsequently affinity-purified using fusion
protein and peptide columns, following the manufac-
turer’s specifications (Bethyl Laboratories, Montgomery,
TX, USA). Negative controls were generated by antis-
era immune depletion using the corresponding columns.
Some experiments were performed using affinity-purified
a-FP2 (a-FP2 pAb) precompeted with FP2 (1:5 mass ra-
tio, overnight rocking at 4◦C).
Protein extraction, immunoprecipitation, and
Western blotting
Samples of normal adult kidneys, liver, and pancreas
were procured in the operating room from tissue speci-
mens resected for carcinoma. Histologic analysis of the
tissue margins assured the absence of carcinogenic in-
volvement of the selected samples. The specimens were
immediately flash frozen in liquid nitrogen and subse-
quently stored at −80◦C.
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Protein extraction followed a previously described pro-
tocol slightly modified [19]. Tissue samples were minced
in liquid nitrogen, homogenized in ice cold homoge-
nization buffer [255 mmol/L sucrose, 20 mmol/L Hepes,
1 mmol/L ethylenediaminetetraacetic acid (EDTA), pH
7.4, and protease inhibitor cocktail (Sigma Chemical Co.,
St. Louis, MO, USA)] with a Potter apparatus and cen-
trifuged at 1000g for 20 minutes at 4◦C to remove nuclei
and cell debris. To obtain membrane fractions, the total
extract, contained within the initial supernatant, was fur-
ther centrifuged at 100,000g for 30 minutes at 4◦C. The
pellet was suspended in ice-cold homogenization buffer,
giving rise to the membrane fraction, while the residual
supernatant included the soluble protein phase.
The immunoprecipitation experiments were carried
out using an affinity-purified antibody/tissue total extract
mass ratio of 20 lg:1.5 mg. The total extract samples were
incubated with a-FP2 pAb in immunoprecipitation buffer
(20 mmol/L sodium phosphate, 150 mmol/L sodium chlo-
ride, 10% glycerol, 1% Triton X-100, pH 7.2, and protease
inhibitor cocktail) and gentle agitation for 2 hours at 4◦C.
A subsequent 2-hour incubation in gentle agitation at 4◦C
was performed following the addition of 60 lL of protein
A sepharose 4 Fast Flow (Amersham Biosciences, Up-
psala, Sweden). The total mix was then centrifuged at
400g for 1 minute and the pellet washed three times, re-
suspended in sodium dodecyl sulfate (SDS) sample buffer
[1.5% SDS, 10 mmol/L Tris HCl, pH 6.8, 0.6% dithiothre-
itol (DTT), and 6% glycerol] and denatured for 3 minutes
at 97◦C.
Western blot analyses were performed using denatured
protein samples and 5% or 7% SDS-polyacrylamide
gel electrophoresis (PAGE), followed by blotting
onto polyvinylidene difluoride (PVDF) (Hybond-P)
(Amersham Biosciences) membranes. The primary im-
munoprobing steps were carried out with nonpurified
and purified antisera, preimmune sera, immune-depleted
sera or precompeted purified antibody, according to the
nature of the experiment. An a-rabbit IgG horseradish
peroxidase (HRP)-conjugated antibody was used for
the secondary immunoprobing step, followed by detec-
tion with the enhanced chemiluminescence (ECL) sys-
tem (Amersham Biosciences). The molecular weight of
the highest band was established by comparison with
a series of high-molecular-weight markers based on
phosphorylase-b cross linking, according to the manufac-
turer’s specifications (phosphorylase-b, cross-linked SDS
molecular weight marker) (Sigma Chemical Co.).
Immunohistochemistry
Paraffin-embedded samples of normal adult kidneys,
livers, pancreas, mammary glands, parotids, colon, and
lung were obtained from medically indicated biopsies or
resections. Mouse embryos were harvested at 9 to 19 dpc
and adult mice were sacrificed at 3 months of age. Em-
bryos and organs were fixed in 10% formalin and embed-
ded in paraffin. Four micrometer human tissue sections
and 3 lm mouse sections were mounted on slides coated
with silane, treated for 20 minutes in steamer with Target
Retrieval System (TRS) (Dako, Carpenteria, CA, USA),
blocked with 50% methanol/3% H2O2, and incubated
with 6% dried nonfat milk in phosphate-buffered saline
(PBS), pH 7.4, for 30 minutes. Primary antibody incuba-
tion was performed at 4◦C for 18 hours in tissue serial
sections. According to the nature of the experiment, the
primary immunoprobing was done with a-FP2 or a-P5P6
antisera, their corresponding preimmune sera (PI), im-
munodepleted a-FP2 sera (a-FP2/dep), a-FP2 pAb or
a-FP2 pAb precompeted with FP2 (a-FP2 pAb/comp).
The immunostaining analyses were performed with both
alkaline phosphatase and peroxidase-based techniques,
except for mouse tissue, since the available appropriate
secondary antibody was peroxidase-conjugated.
Human kidney samples were also probed with
a-aquaporin-2 (Dako) and a-Tamm-Horsfall protein
(kindly provided by C. Bacchi, UNESP, Botucatu, Brazil)
to identify the collecting duct and thick ascending limb
of Henle (TALH), respectively. Secondary antibody
incubation was carried out using EnVision+-alkaline
phosphatase or LSAB (Dako) in human samples and
EnVison+-HRP (Dako) in mouse samples, following the
manufacturer’s orientations. The aquaporin-related ex-
periments were performed with the LSAB peroxidase-
based technique, since the suitable secondary antibody
was peroxidase-conjugated.
Inner medullary collecting duct cells
immunofluorescence
For immunofluorescence studies, we used a well-
characterized, mouse inner medullary collecting duct
cell line (mIMCD-K2) [20]. Cells were grown in Dul-
becco’s modified Eagle’s medium (DMEM)/F12 medium
(BioWhittaker/Fisher catalog number 12-719Q; Spring-
field, NJ, USA) supplemented with 10% fetal bovine
serum (FBS) (BioWhittaker/Fisher catalog number 14-
901E), 100 U/mL penicillin, and 100 mg/mL strepto-
mycin, in 5% CO2/95% air at 37◦C. Stable lines were
selected with 400 lg/mL G418 (BioWhittaker/Fisher
BP-673-5). Cells were plated at confluence on glass
cover slips (Fisher 12-545-82 12CIR-1D). Immunofluo-
rescent studies were performed 3 to 4 days after the
cells were confluent, so as to optimize cell polariza-
tion and cilia formation. Cells were washed with PBS,
fixed with 1% paraformaldehyde, permeabilized with
0.2% Triton X-100, and processed for immunofluores-
cence microscopy as described [21]. Cells were stained
with the following primary antibodies: a-acetylated a-
tubulin (diluted 1:200), a-FP2 pAb (diluted 1:100), and
a-FP2-corresponding preimmune serum (diluted 1:500);
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Fig. 1. Western blot analysis of polyductin.
(A) Kidney total extract samples on 5%
sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), probed with
affinity-purified a-fusion protein 2 (a-FP2
pAb), precompeted a-FP2 pAb, a-FP2, and
depleted a-FP2. (B) Kidney total extract sam-
ples on 5% SDS-PAGE, probed with a-FP2
pAb, a-P5P6, and preimmune serum (PI) cor-
responding to a-P5P6. (C) Kidney total ex-
tract sample on 7% SDS-PAGE, probed with
a-FP2 pAb. (D) Kidney membrane (MF) and
soluble (SF) fractions on 5% SDS-PAGE,
probed with a-FP2 pAb. (E) Liver total ex-
tract samples on 7% SDS-PAGE, probed
with a-FP2 pAb and preimmune serum (PI)
corresponding to a-FP2. (F) Pancreas total
extract (TE), membrane fraction (MF), and
soluble fraction (SF) samples on 7% SDS-
PAGE, probed with a-P5P6 and preim-
mune serum (PI) corresponding to a-P5P6.
Symbols are: ( ), Polyductin-specific bands
described in the text; ( ), ∼380-kD detected
band; see text for detail; ( ), Unspecific
band, detected by preimmune sera and im-
munodepleted sera.
then washed; and incubated with fluorophore-conjugated
secondary antibodies (Molecular Probes, Eugene, OR,
USA). Antibody controls were evaluated to ensure that
the results were not a consequence of cross-reactivity
or nonspecific binding of the secondary antibodies. Nu-
clei were stained with Hoescht 33528 (Sigma Chemical
Co.). Immunofluorescence microscopy was performed on
a Nikon TE200 inverted DIC optics microscope as previ-
ously described [21]. Images were captured digitally using
a Roper Scientific Coolsnap FX-HQ camera and Meta-
Morph (5.0) software.
Immunoelectron microscopy
Samples of normal tissue of human adult kid-
neys obtained from nephrectomy were fixed in 4%
paraformaldehyde, transferred to 0.2% glutaraldehyde
and 4% paraformaldehyde for 2 hours, postfixed in 8%
paraformaldehyde and 2% sucrose in 0.2 mol/L Tris-
buffered saline (TBS), pH 7.4, dehydrated in a graded
ethanol series, and embedded in L.R. White resin (Lon-
don Resin Company, Ltd., Berkshire, England). Thin sec-
tions were cut, mounted on nickel grids, and processed
for immunolabeling using the protein A gold technique
[22], following the protocol previously described [23]. The
grids were rinsed in TBS and incubated in 1% ovalbumin,
fraction V (globulin-free) in TBS-0.05% Tween 20 for 30
minutes. The sections were then incubated overnight at
4◦C with the primary antibody and treated with protein A
colloidal gold particles of 10 nm (Amersham Biosciences)
for 60 minutes at room temperature. The antibody com-
plexes were stabilized with 2% aqueous glutaraldehyde,
stained with 2% aqueous osmium tetroxide, and counter-
stained with aqueous 4% uranyl acetate and Reynolds’
lead citrate. The specimens were examined in a Jeol 1010
transmission electron microscope.
Additional experiments were performed using mouse
renal medullary tissue, using similar techniques for tissue
preparation and signal detection.
RESULTS
Western blot analyses
Total protein extracts, membrane fractions and solu-
ble fractions of human adult normal kidneys, livers, and
pancreas were evaluated by Western blotting. Analyses
with a-FP2 and a-P5P6 demonstrated specific bands of
>440 kD in kidney, pancreas, and liver, and of ∼230 kD
in kidney and liver (Fig. 1). These bands were detected in
total extract and membrane fraction, with weaker signal
also present in kidney and liver supernatants. While a-
FP2 detects the >440 kD band very weakly in lysates, this
signal is strongly and specifically enriched following its
affinity purification. An additional ∼140 kD polypeptide
was specifically detected by both antisera in kidney, liver,
and pancreas total extracts, with a strong signal present
in the supernatants and a weaker signal in the membrane
fractions (Fig. 1). The relative signal intensity between
these bands differed significantly among the samples. A
∼380 kD band, detected by a-FP2, was a variably present
species of unknown significance.
To confirm specificity to polyductin we sought to prove
that the same product could be recognized by antisera
against distinct portions of the molecule. Human kid-
ney total extract was therefore immunoprecipitated with
a-FP2 pAb and subsequently detected by Western blot-
ting with the a-P5P6 (Fig. 2A). These experiments re-
vealed a clear and discrete band of >440 kD, confirming
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Fig. 2. The largest detected PKHD1 product is >440 kD in size and
was immunoprecipitated from kidney total extract. (A) Kidney total
extract (TE) and affinity-purified a-fusion protein 2 (a-FP2 pAb)-
immunoprecipitated TE (IP) samples on 7% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), probed with a-P5P6
and preimmune serum (PI) corresponding to a-P5P6. (B) Kidney TE a-
FP2 pAb-immunoprecipitated (IP) samples run beside high-molecular-
weight markers on 3.5% polyacrylamide gel, probed with a-P5P6 and
preimmune serum (PI) corresponding to a-P5P6. ( ), Immunoprecip-
itated product.
the specificity for the largest protein product. The ∼230
kD band, on its turn, was only very faintly detected by
a-FP2 pAb and a-P5P6 following immunoprecipitation
(data not shown). To better characterize the molecular
weight of the specific top band, additional immunopre-
cipitation followed by Western analyses were performed
using high-molecular-weight markers. Such evaluation
showed that this band lies between the 398.6 kD and
487.0 kD markers, in a position closer to the last of them
(Fig. 2B).
Immunohistochemistry analyses of human adult
normal tissues
Immunohistochemical evaluation of adult normal
human kidney specimens with a-FP2 pAb and a-P5P6
revealed specific staining of cortical and medullary col-
lecting ducts and TALH (Fig. 3A to C). Similar staining
patterns were obtained with both antisera. Immunoprob-
ing with the corresponding preimmune sera, immunode-
pleted sera, and a-FP2 precompeted with FP2 did not
detect these structures. Serial kidney sections were
stained with antibodies a-aquaporin-2, a marker for col-
lecting ducts, and a-Tamm-Horsfall protein, a marker for
TALH. Colocalization of specific staining confirmed the
nephron segment localization pattern described above
(Fig. 3D).
Specific staining was also detected in biliary and pan-
creatic duct epithelia. Signal in hepatocytes and pan-
creatic islets was detected by the antisera, preimmune
sera, and depleted sera, indicating nonspecific staining.
Other ductal structure-containing organs, such as parotid
glands and mammary glands, were also analyzed with
these reagents, but no specific staining was detected. No
specific staining could be seen in heart, brain, and colon
samples either.
Mouse embryos immunohistochemistry analysis
Immunohistochemistry reactions were performed on
sections from paraffin-embedded tissues from 15 to 19
dpc mouse embryos. These studies showed specific stain-
ing in the branching ureteric bud but not in metanephric
mesenchyme, S-shaped bodies and glomeruli (Fig. 4A).
Liver analysis revealed strongly positive signal in intra-
and extrahepatic biliary ducts and in some hepatocytes
from 15 dpc on (Fig. 4B). The surrounding embryonic
blood cells were not stained. Pancreatic ducts were also
strongly stained (Fig. 4C). However, while staining with
a-FP2 pAb showed positive signal in acini, a-P5P6 did
not follow such a pattern, staining the ducts exclusively.
Strong specific staining was detected in 19 dpc salivary
gland with both antibodies (Fig. 4D). As in pancreas, only
a-FP2 pAb detected positive signal in salivary gland acini.
Immune, preimmune, and immune-depleted signals
did not differ significantly in heart, brain, lung, intestine,
and dorsal root ganglia, suggesting nonspecific staining
in these tissues (data not shown).
Immunofluorescence subcellular colocalization studies
The subcellular localization of endogenous polyductin
in inner medullary collecting duct mouse cells was evalu-
ated by immunofluorescence. These studies revealed that
a-FP2 pAb detected a small domain on the apical cell
surface (Fig. 5A), in a distribution that colocalizes with
a-tubulin, a known constituent of the ciliary axoneme
(Fig. 5B and C). This signal was not detected with a-
FP2 preimmune serum. Additional cytoplasmic signal
was also detected by a-FP2 pAb. Though much fainter,
cytoplasmic staining was also detected with the preim-
mune serum. No immunofluorescence signal was ob-
served when secondary antibodies were used alone or
in combination (data not shown).
Immunoelectron microscopy studies
The immunoelectron microscopy analyses on normal
human adult kidney samples and mouse renal medullary
tissue were performed using a-FP2 pAb and a-P5P6.
Studies with both antisera revealed gold-labeled specific
antigens in collecting duct cells. A lower level of signal
was also detected in human TALH cells. Specific signal
could be detected in apical cilium in human and mouse
collecting duct cell samples, while no particles were
detected in cilium in corresponding negative controls
run with precompeted and immunodepleted antisera
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Fig. 3. Immunohistochemical analysis for polyductin in human adult normal kidney samples revealed specific staining in collecting ducts and thick
ascending limb of Henle (TALH). (A) Analyses with affinity-purified a-fusion protein 2 (a-FP2) (a), showing specific collecting duct and TALH
staining in medulla, and with a-FP2 depleted antiserum (b), showing absence of signal in a serial section (original magnification ×200; peroxidase-
based technique). (B) Analyses with a-FP2 pAb (a), showing specific collecting duct and TALH staining in medulla, and with precompeted a-FP2
pAb (b), showing negative staining in a serial section (original magnification ×400; alkaline phosphatase-based technique). (C) Analyses with
a-P5P6 (a and c) and preimmune serum corresponding to a-P5P6 (b and d), showing specific collecting duct staining in cortex (a) and collecting
duct and TALH staining in medulla (c), and negative staining in serial sections (b and d) (original magnification a and b ×200; c and d ×400; alkaline
phosphatase-based technique). (D) Colocalization studies in cortical (a, b, and c) and medullary (d, e, and f) serial sections. a-FP2 (a and d) stains
collecting ducts (red arrow) and TALH (green arrow) in cortex (a) and medulla (d); a-aquaporin 2 (b and e) stains collecting ducts (red arrow)
in cortex (b) and medulla (e); a-Tamm-Horsfall protein (c and f) stains TALH (green arrow) in cortex (c) and medulla (f) (original magnification
×200; a, c, d, and f alkaline phosphatase-based technique).
(Fig. 6A). Positive labeling was identified in the transi-
tion between the basal body and the axoneme and in the
axoneme itself.
Specific labeling was also present in the luminal mem-
brane of human and mouse collecting duct cell samples
(Fig. 6B). Cytoplasmic labeling was detected but appar-
ently not specific, since it was also seen in negative control
experiments with precompeted and immunodepleted an-
tisera. Analyses of proximal tubule cells are also sugges-
tive of nonspecific signal, given that the corresponding
negative control studies revealed approximately the same
level of staining.
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Fig. 4. Immunohistochemical analysis of the developmental polyductin expression profile in mouse embryos. (A) Kidney studies showing specific
ureteric bud and tubular structure staining at 15 dpc (a) probed with affinity-purified a-fusion protein 2 (a-FP2 pAb); (b) probed with a-P5P6; 17
dpc (c) probed with a-FP2 pAb; (d) probed with a-P5P6; and 18 dpc (e) probed with a-P5P6. Glomeruli and S-shaped bodies not stained (original
magnifications a and b ×200; c, d, and e ×400). (B) Liver analysis showing specific staining in biliary ducts and some hepatocytes at 17 dpc (a)
probed with a-FP2 pAb; (b) probed with a-P5P6. Embryonic blood cells not stained (original magnification ×400, extrahepatic biliary duct, arrow).
(C) Pancreas analysis revealing specific staining in pancreatic ducts at 17 dpc (a) probed with a-FP2 pAb; (b) probed with a-P5P6. Acini were
marked exclusively by a-FP2 pAb (a) (original magnification ×200). (D) Salivary gland studies showing specific duct staining at 19 dpc (a) probed
with a-FP2 pAb; (b) probed with a-P5P6. Acini were marked exclusively by a-FP2 pAb (a) (original magnification ×200).
Fig. 5. Immunofluorescence reveals co-localization of polyductin and acetylated a-tubulin in the primary cilium of mouse inner medullary collecting
duct cells grown in culture. (A) Ciliary and cytoplasmic expression of polyductin (green). (B) Expression of acetylated a-tubulin, a primary cilium
marker (red). (C) Merged image (yellow) of (A) and (B) demonstrating colocalization of polyductin and acetylated a-tubulin in cilia.
DISCUSSION
If a significant number of PKHD1 and mouse Pkhd1
alternatively spliced products are translated, their exon
arrangements predict that both membrane-bound and
soluble proteins are produced. Additional lines of ev-
idence support this thesis. First, PKHD1 has high
homology to D86, a mouse protein secreted from lympho-
cytes. Second, Northern blotting with the D86-encoding
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Fig. 6. Immunoelectron microscopy analysis reveals polyductin spe-
cific signal in apical membrane and primary cilium of collecting duct
cells. (A) Specific polyductin expression in primary apical cilium with
affinity-purified a-fusion protein 2 (a-FP2). The image suggests two
cuts in the ciliary structure, giving rise to two distinct portions of the
same apical cilum visualized in this section. The sketch inset (top) in-
dicates the likely cilium orientation. The labeling pattern detected in
the middle portion of the cilium was not observed in any other evalu-
ated structure, strongly suggesting cilium specific labeling and support-
ing the proposed organelle orientation (original magnification ×40000;
bottom inset ×6000). ∗, nucleus; arrows and brackets, gold particles. (B)
Specific polyductin expression in apical membrane detected with a-FP2
(a); control image showing occasional nonspecific labeling with immun-
odepleted a-FP2 (b) [original magnifications a ×60000 (inset ×6000);
b ×60000 (inset ×5000); arrows and brackets, gold particles].
human ortholog, PKHDL1 [24], suggests that this gene
has multiple transcripts, similar to the pattern observed
for PKHD1, and is also expected to generate membrane-
anchored and soluble proteins.
Polyductin shares significant homology to single-pass
cell surface receptors that belong to the Sema superfam-
ily [9, 10, 13]. Such homology, based on the presence
of multiple IPT domains tandemly arranged, suggests
that membrane-bound forms of polyductin, including the
longest ORF product, may also serve as cell surface re-
ceptors. On the other hand, the PbH1 repeats may confer
enzymatic activity to membrane-associated isoforms. In
addition, the products lacking the transmembrane do-
main may function as ligands for as yet to be identified
receptors. Altogether, the final effect of the several poly-
ductin isoforms may be determined by the sum of their
actions, which may change in different tissues, functional
situations, and stages of organ development.
Our Western results identified three potential PKHD1-
related bands in human adult tissues. The top band, of
>440 kD and expressed in kidney, liver, and pancreas,
was detected in total extracts and corresponding mem-
brane fractions, while no signal (in pancreas) or minor
signal (in kidney and liver) was visualized in soluble frac-
tions. The expected size range may be consistent with
the glycosylated form of the longest ORF-encoded pro-
tein and the membrane expression pattern follows this
product’s predicted expression profile. Although similar-
size bands were detected by antisera raised against
different polyductin-derived peptide sequences, more
definitive confirmation that these antibodies recognized
the same polypeptide was carried out using the immuno-
precipitation strategy. We pursued several levels of evi-
dence to confirm specificity of the detected products, in
order to minimize the possibilities of experimental arti-
facts, as experienced in the characterization of polycystin-
1 [25]. Another band of ∼230 kD was detected, showing
a similar expression profile in kidney and liver. This band
likely represents a shorter alternative membrane-bound
isoform with a broad tissue expression profile. The ∼140-
kD band was also specifically detected in kidney, liver,
and pancreas, but shown to be expressed predominantly
in the soluble fraction.
The three products identified in this study may be the
same bands detected by Ward et al in their recent study
[17]. However, there are important differences between
our data and theirs. Our results identify the two shorter
products as isoforms expressed at significantly higher lev-
els than in their study and suggest that the identified bands
comprise membrane-bound and soluble proteins. Ward
et al, on the other hand, suggest that the three bands rep-
resent membrane-associated products. The fact that our
three specific bands are recognized by the a-C-terminus
antiserum and that the ∼140 kD isoform likely repre-
sents a soluble protein strongly suggests that the lower-
molecular-weight products (at least the ∼140 kD protein)
are encoded by alternative transcripts, therefore not cor-
responding to degradation products as suggested by these
authors as a possibility. It is also important to mention that
products detected by the a-C-terminus antibody are not
necessarily membrane-bound. One previously reported,
partially characterized mouse transcript is in fact pre-
dicted to encode a shorter portion of the C-terminus and
not to include the transmembrane domain ([13], product
6.1 of Figure 1). The likely recognition of three distinct
products using only two antibodies indicates that PKHD1
encodes several isoforms, and suggests that a comprehen-
sive design of reagents should lead to the detection of a
considerably higher number of alternative proteins. In ad-
dition, the expression analysis of the currently identified
products supports the existence of membrane-bound and
soluble products. Based on our previous gene expression
data [9], however, one could expect a significantly higher
number of translated products than what we found, even
considering the limited domains used to raise our an-
tibodies. A number of possibilities could explain such
observation: (1) alternatively translated products could
be expressed during specific time periods and/or specific
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tissue/cell types; (2) a significant number of alternative
polypeptides may be generated in very low amounts, not
detected by Western blot; (3) a high number of alterna-
tive transcripts may not be translated; and (4) some of the
smeared Northern blot signal [9] may still be secondary to
mRNA degradation. In addition, a combination of such
possibilities may explain the observed results.
The tissue expression profile evaluated by im-
munohistochemistry showed cortical and medullary
collecting duct staining, a pattern consistent with the his-
tologic features seen in ARPKD. The TALH staining,
on its turn, was not a previously expected overlapping
signal, but careful microdissection of ARPKD kidneys
evidenced in approximately 30% of the cases that the
angle of the loop of Henle was dilated [26]. Our data
were confirmed by double staining with tubular specific
markers (a-aquaporin-2 and a-Tamm-Horsfall protein)
in serial kidney sections to assure structure specificity.
On the other hand, it is important to mention that the
described staining pattern was obtained in adult human
kidney and thus likely reflects the functional tubular dis-
tribution of polyductin in the terminally differentiated
organ. While a similar staining pattern was described by
Ward et al in collecting ducts, they report positive signal in
TALH in human infantile kidney, but not in adult kidney.
We presently do not have an explanation for the reported
differences. The presence of biliary duct staining is consis-
tent with the biliary dysgenesis associated with ARPKD
and similarly suggests the potentiality for PKHD1 func-
tion in mature liver. Specific staining in pancreatic ducts
may be also compatible with ARPKD phenotype [27].
Overall, the immunohistochemical profile was consistent
with Northern and in situ hybridization analyses previ-
ously performed in multiple human and mouse tissues [9,
13]. The liver and pancreas expression profile followed
the basic pattern reported by Ward et al [17]. In our case,
however, the faint staining in hepatocytes and pancreatic
islets were likely unspecific.
Staining of the branching ureteric bud suggests that the
subsequent ARPKD collecting duct abnormalities occur
as a consequence of a primary defect in this structure. The
absence of specific staining in metanephric mesenchyme,
S-shaped bodies, and glomeruli are in accordance with
the apparent limited involvement of other nephron seg-
ments in the pathogenesis of ARPKD. Strong specific
staining in intra- and extrabiliary ducts are also con-
sistent with the hypothesis of maturational abnormality
of biliary and renal tubuloepithelial differentiation pro-
posed for ARPKD. Positive signal in pancreatic ducts
also supports the concept that polyductin is involved in
some ductal epithelia terminal differentiation. In addi-
tion, the acinar staining pattern seen in pancreas and
salivary gland is consistent with the existence of structure-
specific transcripts, as previously reported [13]. The pres-
ence of specific staining in some hepatocytes in the later
phases of mouse liver development, not detected in hu-
man adult hepatocytes, raises the possibility that the pos-
itively stained fetal cells might differentiate into other
cell types, contributing to the biliary tract formation [28].
The lack of staining in tubule-epithelial structures such
as human salivary and mammary glands may suggest that
polyductin is not ubiquitously expressed in adult tubular
epithelia, although the used reagents might have been un-
able to detect true expression. The strong specific staining
seen in ducts of mouse salivary glands at 19 dpc, however,
may be consistent with a broad polyductin expression in
tubular epithelia of developing tissues.
Immunofluorescence analysis of cultured inner
medullary collecting duct cells and immunoelectron
microscopy of renal collecting duct revealed positive
signal in primary cilium, both in axoneme and basal
body-axoneme transition. Our results are consistent with
the data of Ward et al describing positive polyductin
staining in canine-derived MDCK cell cilia [17]. Poly-
ductin, therefore, constitutes one more PKD-related
protein expressed in the primary apical cilium, empha-
sizing the possible fundamental role of cilium in ductal
epithelia differentiation and the critical contribution
of cilial structural or functional defects in renal cystic
disease pathogenesis. The PKD-associated set of proteins
expressed in cilia has now been broadened to include
polycystins 1 and 2, cystin, polaris, inversin, nephrocystin,
polyductin, and very likely nephrocystin-3 [21, 29–32].
Cilia may sense physical or chemical stimuli/variations
and transduce the signals via intracellular calcium
transients [33]. It has been postulated that polycystins 1
and 2 may regulate intracellular calcium influx, a process
activated by cilia movement [34–36]. Since the primary
apical cilium may potentially modulate centriolar func-
tion, these signals may control the growth of kidney
epithelial cells, allowing them to terminally differentiate
and form mature renal tubules, a process that has been
investigated in depth [37, 38]. The precise nature of how
these cystoproteins, including polyductin, contribute to
this process, however, is presently unknown.
The detection of polyductin in apical membrane and
in cytoplasm suggests that it has functional roles be-
yond its cilia-related functions and thus, by extension,
the pathogenesis of ARPKD likely involves disruptions
in other subcellular domains. Polyductin expression in
the luminal membrane raises the possibility of multi-
ple functional roles for the membrane-bound isoforms.
They may behave as apical-membrane anchored re-
ceptors, a less common localization for cell receptors,
but a well-documented fact [39–41]. Various combina-
tions of middle domains in membrane-associated prod-
ucts may contribute to the generation of receptors with
distinct binding specificities or affinities, an interesting
hypothesis for a developmental disorder. In this case,
response to ligands may vary by organ and stages of
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differentiation/maturation. In addition, the presence of
an alternative number of PbH1 repeats in different prod-
ucts could also allow variation in the recognition of dif-
ferent glycoproteins, leading to specific interactions with
extracellular matrix or neighboring cells. The demonstra-
tion of cytoplasmic staining for polyductin and the fact
that one of the specific products identified by Western
blot is likely a soluble protein support an additional ligand
role for a group of polyductin isoforms. Similar promi-
nent splicing variations have been seen in the neurexin
gene family, promoting significant structural and func-
tional variability [42, 43].
This potential complex mechanism, along with mis-
sense mutations scattered throughout PKHD1 in
ARPKD patients, supports the potential existence of a
large number of hypomorphic alleles, and suggests that
the combination of pathogenic mutations may be a key
feature in establishing the final disease phenotype. We
believe that the progressive characterization of PKHD1
products will be essential to analyze the questions raised
in this report. These studies will likely include eukary-
otic cell transfection models and will naturally extend to
the generation of various PKHD1-targeted mouse mod-
els. The detailed characterization presented in this work
should contribute to the future studies to further define
the complex function of polyductin and the molecular
and functional basis of ARPKD pathogenesis.
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